Sanofi, the French biopharmaceutical giant under CEO Paul Hudson, has been maneuvering through a momentous shift from a consumer health company to a pure biopharma playing a major role in R&D investments. Engaging in advanced areas such as
AI, generative physics, and
mRNA research, the company strengthens its pharmaceutical product portfolio with recent achievements. Its BTK inhibitor has shown promising results in phase 3 trials, raising platelet levels in some patients.
Dupixent, a drug for young EoE patients, recently got the green light from EMA. Additionally, Sanofi's profitability has increased, backed by early vaccine sales and Dupixent's continued growth. The firm also struck a deal with CD&R and French government to sell off a part of its consumer health arm, pursuing a more biopharma-focused model. Amid the negotiations, workers are set to strike over the sale and job security concerns. Their commitment to environmental sustainability is reflected in their COP28 participation, supporting healthcare sector decarbonization. Sanofi's profits have also been notably bolstered by Beyfortus and vaccine sales. However, multiple sclerosis drug research continues, with some trials yielding mixed outcomes. It has also secured major investments for new production facilities and Paris 2024 Olympics involvement.
Sanofi News Analytics from Fri, 09 Feb 2024 08:00:00 GMT to Sun, 10 Nov 2024 00:25:29 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
